Management of Lead Encephalopathy with DMSA After Exposure to Lead-Contaminated Moonshine

@article{Arnold2015ManagementOL,
  title={Management of Lead Encephalopathy with DMSA After Exposure to Lead-Contaminated Moonshine},
  author={Justin M Arnold and Brent Morgan},
  journal={Journal of Medical Toxicology},
  year={2015},
  volume={11},
  pages={464-467}
}
Lead encephalopathy is a severe manifestation of lead poisoning that can present with altered mental status and seizures and has been associated with illicit moonshine consumption. Lead encephalopathy has traditionally been treated using dimercaprol (British anti-Lewisite, BAL) and calcium disodium ethylenediaminetetraacetic acid (CaNa2EDTA). We describe a patient with lead encephalopathy related to lead-contaminated moonshine consumption, who was treated using dimercaptosuccinic acid (DMSA… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 10 references

The metabolism of C14 labeled ethylenediaminetetraacetic acid in human beings.

The Journal of laboratory and clinical medicine • 1954
View 3 Excerpts
Highly Influenced

Antidote Shortages in the USA: Impact and Response

Journal of Medical Toxicology • 2013

The prevalence of pharmaceutical shortages in the United States

P Le, E Seoane-Vazquez, +3 authors AR Dunehew
J Generic Med • 2011

Succimer, an oral lead chelator.

Clinical pharmacy • 1991
View 1 Excerpt

2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans.

Medical toxicology and adverse drug experience • 1988
View 2 Excerpts

Similar Papers

Loading similar papers…